28/05/2020 |
ATENEA-Co-300 study |
CIGB |
Registered outdated |
01/03/2021 |
AVATAR-2020 |
CIGB |
Registered outdated |
11/08/2020 |
DALIA Study |
CIGB |
Registered outdated |
14/05/2020 |
CIGB-258 at COVID-19 |
CIGB |
Registered outdated |
22/06/2020 |
VIDA study |
CIGB |
Registered outdated |
14/07/2020 |
Safety and immunogenicity of the CIGB 2020. |
CIGB |
Registered outdated |
01/10/2020 |
OLIVO Study |
CIGB |
Registered |
26/11/2020 |
ABDALA Clinical Study |
CIGB |
Registered outdated |
26/11/2020 |
MAMBISA Study |
CIGB |
Registered outdated |
11/03/2021 |
CIGB2020- ARI elderly contacts |
CIGB |
Registered outdated |
18/03/2021 |
ABDALA Clinical Study - Phase III |
CIGB |
Registered |
27/03/2021 |
ABDALA-Intervention |
CIGB |
Registered |
09/07/2021 |
CIGB-Mambisa/Abdala in convalescents |
CIGB |
Registered outdated |
01/07/2021 |
Evaluation of the safety and immunogenicity of the vaccine candidate "ABDALA" in children and adolescents |
CIGB |
Registered |
03/09/2021 |
MEÑIQUE Study |
CIGB |
Registered |
20/04/2022 |
Jusvinza in rheumatoid arthritis |
CIGB |
Registered |
06/12/2022 |
Nasal recombinant human interferon alfa-2b in ARI |
CIGB |
Registered |
29/07/2022 |
Nasalferon in ARI |
CIGB |
Registered |
06/07/2023 |
Exploratory study to evaluate the effect and safety of CIGB 500 in seriously ill patients with shock |
CIGB |
Registered |
24/04/2023 |
Efficacy and safety of Jusvinza treatment in patients with acute respiratory distress syndrome. Phase II/III |
CIGB |
Registered |